The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Clinical Trials for Ustekinumab & Denosumab Biosimilars Begin Recruitment

New Clinical Trials for Ustekinumab & Denosumab Biosimilars Begin Recruitment

March 17, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Ustekinumab Biosimilar
On March 1, Bioepsis Samsung announced it will begin phase 1 clinical trials for SB17, which is biosimilar to ustekinumab (Stelara), a humanized monoclonal antibody against interleukins 12 and 23.1 The randomized, double-blind, clinical trial will be a three-arm, parallel study comparing the pharmacokinetics, safety, tolerability and immunogenicity of a 45 mg dose of subcutaneous ustekinumab with SB17 in healthy male volunteers (NCT04772274).2

You Might Also Like
  • FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin
  • Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
Also By This Author
  • Biosimilar Drugs for RA Studied in Multiple Trials

In 2009, the U.S. Food & Drug Administration (FDA) approved ustekinumab to treat adult patients with moderate to severe plaque psoriasis.3 In 2013, the biologic agent received FDA approval for the treatment of psoriatic arthritis as monotherapy or in combination with methotrexate.4 Ustekinumab is also approved for the treatment of inflammatory bowel disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Recruiting for SB16 Trials
Two phase 3 clinical trials of SB16, which is biosimilar to denosumab (Prolia), have begun recruiting patients. The first is a randomized, double-blind, multi-center study evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of SB16 compared with denosumab in postmenopausal women with osteoporosis (NCT04664959). Patients will receive 60 mg of subcutaneous SB16 or denosumab every six months for up to 12 months.5

The second phase 3 trial is recruiting healthy men to study the pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity of SB16 given as a single 60 mg dose (NCT04621318).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

All studies are ongoing.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Samsung Bioepis Co. Ltd. News release: Samsung Bioepis initiates phase 1 clinical trial for SB17, proposed biosimilar to Stelara (ustekinumab). 2021 Mar 1.
  2. Samsung Bioepis Co. Ltd. A study to compare SB17 (proposed ustekinumab biosimilar) to E.U. sourced Stelara and U.S. sourced Stelara in healthy male subjects. ClinicalTrials.gov. 2021 Feb 26.
  3. U.S. Food & Drug Administration. Stelara (ustekinumab) FDA approval letter. 2020 Dec 30.
  4. U.S. Food & Drug Administration. Stelera (ustekinumab) approval letter for psoriatic arthritis. 2013 Sep 20.
  5. Samsung Bioepis Co. Ltd. A study to compare SB16 (proposed denosumab biosimilar) to Prolia in postmenopausal women with osteoporosis. ClinicalTrials.gov. 2020 Dec 11.
  6. Samsung Bioepis Co. Ltd. Pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity study of SB16 in healthy male subjects. ClinicalTrials.gov. 2020 Nov 9.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: biosimilar, clinical trials, denosumab, SB16, SB17, ustekinumab

You Might Also Like:
  • FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin
  • Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • Samsung Bioepis Receives Final European Approval for Its Remicade Copy

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.